AU2010227224A1 - Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators - Google Patents

Info

Publication number

AU2010227224A1

AU2010227224A1 AU2010227224A AU2010227224A AU2010227224A1 AU 2010227224 A1 AU2010227224 A1 AU 2010227224A1 AU 2010227224 A AU2010227224 A AU 2010227224A AU 2010227224 A AU2010227224 A AU 2010227224A AU 2010227224 A1 AU2010227224 A1 AU 2010227224A1

Authority

AU

Australia

Prior art keywords

dioxo

thiazol

thiazolo

tetrahydro

dimethyl

Prior art date

2009-03-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 title claims description 7
• 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 title claims description 5
• CBFZADDDBQLSPS-UHFFFAOYSA-N [1,2]thiazolo[4,3-d]pyrimidine 2,2-dioxide Chemical class N1=CN=CC2=NS(=O)(=O)C=C21 CBFZADDDBQLSPS-UHFFFAOYSA-N 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 184
• 238000000034 method Methods 0.000 claims abstract description 133
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
• 201000010099 disease Diseases 0.000 claims abstract description 15
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
• -1 cyano, hydroxyl Chemical group 0.000 claims description 53
• 125000000217 alkyl group Chemical group 0.000 claims description 48
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 46
• 229910052739 hydrogen Inorganic materials 0.000 claims description 31
• 239000001257 hydrogen Substances 0.000 claims description 30
• 125000003118 aryl group Chemical group 0.000 claims description 29
• 208000002193 Pain Diseases 0.000 claims description 27
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
• 238000010992 reflux Methods 0.000 claims description 23
• 239000000203 mixture Substances 0.000 claims description 22
• 125000001072 heteroaryl group Chemical group 0.000 claims description 21
• 125000000623 heterocyclic group Chemical group 0.000 claims description 21
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
• 150000003839 salts Chemical class 0.000 claims description 21
• 125000001188 haloalkyl group Chemical group 0.000 claims description 19
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
• 125000003545 alkoxy group Chemical group 0.000 claims description 17
• 229910052736 halogen Inorganic materials 0.000 claims description 17
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
• 150000002367 halogens Chemical class 0.000 claims description 16
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 15
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 15
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 14
• 125000003342 alkenyl group Chemical group 0.000 claims description 13
• 150000002431 hydrogen Chemical class 0.000 claims description 13
• 125000000304 alkynyl group Chemical group 0.000 claims description 12
• 208000035475 disorder Diseases 0.000 claims description 12
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 12
• 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 12
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 11
• 229910052757 nitrogen Inorganic materials 0.000 claims description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
• 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 10
• 101150018425 Cr1l gene Proteins 0.000 claims description 8
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
• 208000024891 symptom Diseases 0.000 claims description 8
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 7
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 7
• 125000004122 cyclic group Chemical group 0.000 claims description 7
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 7
• 208000004296 neuralgia Diseases 0.000 claims description 7
• 229910052717 sulfur Inorganic materials 0.000 claims description 7
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 7
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
• 208000000094 Chronic Pain Diseases 0.000 claims description 6
• 150000005347 biaryls Chemical group 0.000 claims description 6
• 239000003085 diluting agent Substances 0.000 claims description 6
• 125000005842 heteroatom Chemical group 0.000 claims description 6
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
• 208000021722 neuropathic pain Diseases 0.000 claims description 5
• 201000001119 neuropathy Diseases 0.000 claims description 5
• 230000007823 neuropathy Effects 0.000 claims description 5
• 229920006395 saturated elastomer Polymers 0.000 claims description 5
• 239000011593 sulfur Substances 0.000 claims description 5
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
• 208000026935 allergic disease Diseases 0.000 claims description 3
• 230000002917 arthritic effect Effects 0.000 claims description 3
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
• ZLSBGGFBYHZNRJ-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(Cl)=C1 ZLSBGGFBYHZNRJ-UHFFFAOYSA-N 0.000 claims description 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
• 230000003349 osteoarthritic effect Effects 0.000 claims description 3
• 208000009935 visceral pain Diseases 0.000 claims description 3
• IWWAGQACCJZWGI-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)-n-[4-[4-fluoro-3-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(OC(F)(F)F)=C1 IWWAGQACCJZWGI-UHFFFAOYSA-N 0.000 claims description 2
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 2
• 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
• 208000008035 Back Pain Diseases 0.000 claims description 2
• 206010058019 Cancer Pain Diseases 0.000 claims description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 2
• 206010011224 Cough Diseases 0.000 claims description 2
• 201000004624 Dermatitis Diseases 0.000 claims description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
• 208000001640 Fibromyalgia Diseases 0.000 claims description 2
• 206010020751 Hypersensitivity Diseases 0.000 claims description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
• 208000019695 Migraine disease Diseases 0.000 claims description 2
• 208000028389 Nerve injury Diseases 0.000 claims description 2
• 206010030216 Oesophagitis Diseases 0.000 claims description 2
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
• 208000004550 Postoperative Pain Diseases 0.000 claims description 2
• 208000003251 Pruritus Diseases 0.000 claims description 2
• 201000004681 Psoriasis Diseases 0.000 claims description 2
• 208000008765 Sciatica Diseases 0.000 claims description 2
• 206010046543 Urinary incontinence Diseases 0.000 claims description 2
• 206010047700 Vomiting Diseases 0.000 claims description 2
• 208000006673 asthma Diseases 0.000 claims description 2
• 208000010668 atopic eczema Diseases 0.000 claims description 2
• 201000003146 cystitis Diseases 0.000 claims description 2
• 208000000718 duodenal ulcer Diseases 0.000 claims description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
• 230000009610 hypersensitivity Effects 0.000 claims description 2
• 208000027866 inflammatory disease Diseases 0.000 claims description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
• 208000028867 ischemia Diseases 0.000 claims description 2
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
• 206010027599 migraine Diseases 0.000 claims description 2
• 201000006417 multiple sclerosis Diseases 0.000 claims description 2
• YPLDZKGKWINHEO-UHFFFAOYSA-N n-[1-(4-bromophenyl)pyrazol-3-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(=N1)C=CN1C1=CC=C(Br)C=C1 YPLDZKGKWINHEO-UHFFFAOYSA-N 0.000 claims description 2
• OPLCKZVWSAXDFY-UHFFFAOYSA-N n-[1-(4-bromophenyl)pyrazol-3-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(=N1)C=CN1C1=CC=C(Br)C=C1 OPLCKZVWSAXDFY-UHFFFAOYSA-N 0.000 claims description 2
• POXWZXDNVWIHJW-UHFFFAOYSA-N n-[4-(4-bromophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC=C(Br)C=C1 POXWZXDNVWIHJW-UHFFFAOYSA-N 0.000 claims description 2
• XQMBHQKEVKETDZ-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 XQMBHQKEVKETDZ-UHFFFAOYSA-N 0.000 claims description 2
• YJZIYUPBADALKY-UHFFFAOYSA-N n-[4-(4-tert-butylphenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(C(C)(C)C)C=C1 YJZIYUPBADALKY-UHFFFAOYSA-N 0.000 claims description 2
• KZQDZUKAGPBBST-UHFFFAOYSA-N n-[4-[2,4-difluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(C(F)(F)F)=C1F KZQDZUKAGPBBST-UHFFFAOYSA-N 0.000 claims description 2
• RGXHZTKDEOKUAJ-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(C(F)(F)F)=C1 RGXHZTKDEOKUAJ-UHFFFAOYSA-N 0.000 claims description 2
• VTBLEPLWRAMIAO-UHFFFAOYSA-N n-[5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(S1)=NN=C1C1=CC=C(Br)C=C1 VTBLEPLWRAMIAO-UHFFFAOYSA-N 0.000 claims description 2
• 230000008764 nerve damage Effects 0.000 claims description 2
• 230000004770 neurodegeneration Effects 0.000 claims description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 2
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
• 150000003233 pyrroles Chemical class 0.000 claims description 2
• 208000023504 respiratory system disease Diseases 0.000 claims description 2
• 210000002784 stomach Anatomy 0.000 claims description 2
• 229930192474 thiophene Natural products 0.000 claims description 2
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
• 125000001246 bromo group Chemical group Br* 0.000 claims 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
• 125000001309 chloro group Chemical group Cl* 0.000 claims 2
• 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
• 150000000177 1,2,3-triazoles Chemical class 0.000 claims 1
• OFGJUYAHVNDPDE-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-(2-hexylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound CCCCCCC1=CC=CC=C1C1=CSC(NC(=O)CC=2C=3C(=O)N(C)C(=O)N(C)C=3SN=2)=N1 OFGJUYAHVNDPDE-UHFFFAOYSA-N 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1
• 239000000543 intermediate Substances 0.000 abstract description 67
• 230000015572 biosynthetic process Effects 0.000 abstract description 14
• 238000003786 synthesis reaction Methods 0.000 abstract description 13
• 230000001052 transient effect Effects 0.000 abstract description 4
• KFPREKBZXDIMQJ-UHFFFAOYSA-N [1,2]thiazolo[3,4-d]pyrimidine 2,2-dioxide Chemical compound C1=NC=NC2=NS(=O)(=O)C=C21 KFPREKBZXDIMQJ-UHFFFAOYSA-N 0.000 abstract description 2
• AMKLYVPTLKOMBX-UHFFFAOYSA-N [1,2]thiazolo[5,4-d]pyrimidine 1,1-dioxide Chemical class N1=CN=C2S(=O)(=O)N=CC2=C1 AMKLYVPTLKOMBX-UHFFFAOYSA-N 0.000 abstract description 2
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 102
• 239000007787 solid Substances 0.000 description 67
• 239000000047 product Substances 0.000 description 60
• 238000010168 coupling process Methods 0.000 description 57
• 238000005859 coupling reaction Methods 0.000 description 57
• 230000008878 coupling Effects 0.000 description 54
• 238000005481 NMR spectroscopy Methods 0.000 description 53
• 239000002904 solvent Substances 0.000 description 48
• 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 45
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 38
• 239000012312 sodium hydride Substances 0.000 description 38
• 229910000104 sodium hydride Inorganic materials 0.000 description 38
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 32
• 239000006185 dispersion Substances 0.000 description 32
• 239000002480 mineral oil Substances 0.000 description 32
• 235000010446 mineral oil Nutrition 0.000 description 32
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
• 239000002585 base Substances 0.000 description 25
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 23
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 16
• 238000006243 chemical reaction Methods 0.000 description 16
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 16
• 239000011541 reaction mixture Substances 0.000 description 16
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 15
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
• 239000000243 solution Substances 0.000 description 15
• 150000001412 amines Chemical class 0.000 description 14
• 239000007822 coupling agent Substances 0.000 description 13
• 238000013459 approach Methods 0.000 description 12
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 12
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 11
• 150000002148 esters Chemical class 0.000 description 11
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
• 102000005962 receptors Human genes 0.000 description 11
• 108020003175 receptors Proteins 0.000 description 11
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
• VELJPMSTOCSDTL-UHFFFAOYSA-N 3-methylsulfanyl-[1,2]thiazolo[3,4-d]pyrimidine 2,2-dioxide Chemical compound C1=NC=NC2=NS(=O)(=O)C(SC)=C21 VELJPMSTOCSDTL-UHFFFAOYSA-N 0.000 description 9
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 125000004432 carbon atom Chemical group C* 0.000 description 9
• 238000001914 filtration Methods 0.000 description 9
• 238000011282 treatment Methods 0.000 description 9
• 229910052799 carbon Inorganic materials 0.000 description 8
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
• 210000004027 cell Anatomy 0.000 description 8
• 239000000460 chlorine Substances 0.000 description 8
• 229910052731 fluorine Inorganic materials 0.000 description 8
• 150000004820 halides Chemical class 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 7
• 150000008062 acetophenones Chemical class 0.000 description 7
• 229910052740 iodine Inorganic materials 0.000 description 7
• 239000012299 nitrogen atmosphere Substances 0.000 description 7
• 230000003647 oxidation Effects 0.000 description 7
• 238000007254 oxidation reaction Methods 0.000 description 7
• 238000005160 1H NMR spectroscopy Methods 0.000 description 6
• BTHQWHPQSPRHJU-UHFFFAOYSA-N 2,4-dioxo-1H-pyrimidine-5-carbodithioic acid Chemical compound C1=C(C(=O)NC(=O)N1)C(=S)S BTHQWHPQSPRHJU-UHFFFAOYSA-N 0.000 description 6
• PVJDWZZIIOOQRB-UHFFFAOYSA-N 2-([1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetic acid Chemical compound C1=NC=C2C(CC(=O)O)=NSC2=N1 PVJDWZZIIOOQRB-UHFFFAOYSA-N 0.000 description 6
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
• 229960000583 acetic acid Drugs 0.000 description 6
• ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 6
• 150000001408 amides Chemical class 0.000 description 6
• 229910052794 bromium Inorganic materials 0.000 description 6
• 150000001721 carbon Chemical group 0.000 description 6
• 229910052801 chlorine Inorganic materials 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 239000011630 iodine Substances 0.000 description 6
• 210000000929 nociceptor Anatomy 0.000 description 6
• 125000003944 tolyl group Chemical group 0.000 description 6
• RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 230000000694 effects Effects 0.000 description 5
• 125000005843 halogen group Chemical group 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• IYCKMNAVTMOAKD-UHFFFAOYSA-N 1,2-thiazol-3-amine Chemical compound NC=1C=CSN=1 IYCKMNAVTMOAKD-UHFFFAOYSA-N 0.000 description 4
• IHZUNTQSYXPNIC-UHFFFAOYSA-N 2,4-dioxo-6-sulfanyl-1h-pyrimidine-5-carbonitrile Chemical class SC=1NC(=O)NC(=O)C=1C#N IHZUNTQSYXPNIC-UHFFFAOYSA-N 0.000 description 4
• VATQPUHLFQHDBD-UHFFFAOYSA-N 6-chloro-1,3-dimethylpyrimidine-2,4-dione Chemical compound CN1C(Cl)=CC(=O)N(C)C1=O VATQPUHLFQHDBD-UHFFFAOYSA-N 0.000 description 4
• KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 4
• QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
• 208000001294 Nociceptive Pain Diseases 0.000 description 4
• 101150095096 TRPM2 gene Proteins 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 238000005933 dealkoxycarbonylation reaction Methods 0.000 description 4
• 150000005690 diesters Chemical class 0.000 description 4
• 238000001704 evaporation Methods 0.000 description 4
• 230000008020 evaporation Effects 0.000 description 4
• 230000007062 hydrolysis Effects 0.000 description 4
• 238000006460 hydrolysis reaction Methods 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
• GZDIUHKAZLMQFJ-UHFFFAOYSA-N 1-(4-bromophenyl)pyrazol-3-amine Chemical compound N1=C(N)C=CN1C1=CC=C(Br)C=C1 GZDIUHKAZLMQFJ-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 description 3
• 108091006146 Channels Proteins 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• GUKXTBPVCMJWMV-UHFFFAOYSA-N N-([1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical class C(C)(=O)NC=1SN=C2N=CN=CC2=1 GUKXTBPVCMJWMV-UHFFFAOYSA-N 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 3
• 102000003565 TRPV2 Human genes 0.000 description 3
• 102000003568 TRPV3 Human genes 0.000 description 3
• 102000003570 TRPV5 Human genes 0.000 description 3
• 102000003569 TRPV6 Human genes 0.000 description 3
• 101150096736 TRPV6 gene Proteins 0.000 description 3
• 101150077905 Trpv2 gene Proteins 0.000 description 3
• 101150043371 Trpv3 gene Proteins 0.000 description 3
• 101150034091 Trpv5 gene Proteins 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 235000016720 allyl isothiocyanate Nutrition 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 230000032050 esterification Effects 0.000 description 3
• 238000005886 esterification reaction Methods 0.000 description 3
• 125000001153 fluoro group Chemical group F* 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 108091008700 nociceptors Proteins 0.000 description 3
• 230000001473 noxious effect Effects 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 239000012047 saturated solution Substances 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
• 235000019345 sodium thiosulphate Nutrition 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• ZNKXTIAQRUWLRL-UHFFFAOYSA-M sodium;sulfane;hydroxide Chemical compound O.[Na+].[SH-] ZNKXTIAQRUWLRL-UHFFFAOYSA-M 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• KRQFEURBUJROHA-UHFFFAOYSA-N 3-(4-chlorophenyl)-1,2-oxazol-5-amine Chemical compound O1C(N)=CC(C=2C=CC(Cl)=CC=2)=N1 KRQFEURBUJROHA-UHFFFAOYSA-N 0.000 description 2
• UWAXMUSNRIUHRQ-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(Cl)C(Cl)=CC=2)=C1 UWAXMUSNRIUHRQ-UHFFFAOYSA-N 0.000 description 2
• DWGWNNCHJPKZNC-UHFFFAOYSA-N 4-(4-chlorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC(Cl)=CC=2)=C1 DWGWNNCHJPKZNC-UHFFFAOYSA-N 0.000 description 2
• UYSJHSJNYGOZHN-UHFFFAOYSA-N 4-[2,4-difluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=C(C(F)=CC=2)C(F)(F)F)F)=C1 UYSJHSJNYGOZHN-UHFFFAOYSA-N 0.000 description 2
• QTFIQKQWACKFHA-UHFFFAOYSA-N 4-[2-fluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=C(C=CC=2)C(F)(F)F)F)=C1 QTFIQKQWACKFHA-UHFFFAOYSA-N 0.000 description 2
• JMFDDPJIEZLCAR-UHFFFAOYSA-N 4-[3,5-difluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(F)C(=C(F)C=2)C(F)(F)F)=C1 JMFDDPJIEZLCAR-UHFFFAOYSA-N 0.000 description 2
• ZZDBATBJNFVJCB-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(C=CC=2)C(F)(F)F)=C1 ZZDBATBJNFVJCB-UHFFFAOYSA-N 0.000 description 2
• VCMSBRUFWBYGNR-UHFFFAOYSA-N 4-[3-fluoro-4-(trifluoromethoxy)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(F)C(OC(F)(F)F)=CC=2)=C1 VCMSBRUFWBYGNR-UHFFFAOYSA-N 0.000 description 2
• OPHDOIKOSGCXPW-UHFFFAOYSA-N 4-[3-fluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(F)C(=CC=2)C(F)(F)F)=C1 OPHDOIKOSGCXPW-UHFFFAOYSA-N 0.000 description 2
• SKFDQIWSTJNSAU-UHFFFAOYSA-N 4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(C(Cl)=CC=2)C(F)(F)F)=C1 SKFDQIWSTJNSAU-UHFFFAOYSA-N 0.000 description 2
• OXROOSXUSPSVNY-UHFFFAOYSA-N 4-[4-fluoro-3-(trifluoromethoxy)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(OC(F)(F)F)C(F)=CC=2)=C1 OXROOSXUSPSVNY-UHFFFAOYSA-N 0.000 description 2
• KNFZBJVESBZZMI-UHFFFAOYSA-N 5-(4-bromophenyl)-1,3,4-thiadiazol-2-amine Chemical compound S1C(N)=NN=C1C1=CC=C(Br)C=C1 KNFZBJVESBZZMI-UHFFFAOYSA-N 0.000 description 2
• XQPBZIITFQHIDI-UHFFFAOYSA-N 5-(4-chlorophenyl)-1h-pyrazol-3-amine Chemical compound N1N=C(N)C=C1C1=CC=C(Cl)C=C1 XQPBZIITFQHIDI-UHFFFAOYSA-N 0.000 description 2
• NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
• 108010049777 Ankyrins Proteins 0.000 description 2
• 102000008102 Ankyrins Human genes 0.000 description 2
• 101800004538 Bradykinin Proteins 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
• 101000605625 Homo sapiens Polycystic kidney disease 2-like 1 protein Proteins 0.000 description 2
• 101000605623 Homo sapiens Polycystic kidney disease 2-like 2 protein Proteins 0.000 description 2
• 101001074444 Homo sapiens Polycystin-1 Proteins 0.000 description 2
• 101001074439 Homo sapiens Polycystin-2 Proteins 0.000 description 2
• 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 description 2
• 101000844521 Homo sapiens Transient receptor potential cation channel subfamily M member 5 Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 102100035792 Kininogen-1 Human genes 0.000 description 2
• 102100026502 Mucolipin-1 Human genes 0.000 description 2
• 102100030870 Mucolipin-2 Human genes 0.000 description 2
• 102100030868 Mucolipin-3 Human genes 0.000 description 2
• VXWNGJJTIMMEKI-UHFFFAOYSA-N N-([1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical class C(C)(=O)NC1=NSC2=NC=NC=C21 VXWNGJJTIMMEKI-UHFFFAOYSA-N 0.000 description 2
• LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 102100038330 Polycystic kidney disease 2-like 1 protein Human genes 0.000 description 2
• 102100038335 Polycystic kidney disease 2-like 2 protein Human genes 0.000 description 2
• 102100036143 Polycystin-1 Human genes 0.000 description 2
• 102100036142 Polycystin-2 Human genes 0.000 description 2
• 101100482470 Rattus norvegicus Trpa1 gene Proteins 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• 108060008646 TRPA Proteins 0.000 description 2
• 102000027549 TRPC Human genes 0.000 description 2
• 108060008648 TRPC Proteins 0.000 description 2
• 102000003623 TRPC6 Human genes 0.000 description 2
• 102000027545 TRPM Human genes 0.000 description 2
• 108091008847 TRPM Proteins 0.000 description 2
• 102000003615 TRPM2 Human genes 0.000 description 2
• 102000003620 TRPM3 Human genes 0.000 description 2
• 108060008547 TRPM3 Proteins 0.000 description 2
• 102000003618 TRPM4 Human genes 0.000 description 2
• 102000003611 TRPM7 Human genes 0.000 description 2
• 102000027544 TRPML Human genes 0.000 description 2
• 108091008846 TRPML Proteins 0.000 description 2
• 108060009332 TRPP Proteins 0.000 description 2
• 102000003563 TRPV Human genes 0.000 description 2
• 108060008564 TRPV Proteins 0.000 description 2
• 102000003566 TRPV1 Human genes 0.000 description 2
• 102000003567 TRPV4 Human genes 0.000 description 2
• 101150098315 TRPV4 gene Proteins 0.000 description 2
• 102100031234 Transient receptor potential cation channel subfamily M member 2 Human genes 0.000 description 2
• 102100031215 Transient receptor potential cation channel subfamily M member 5 Human genes 0.000 description 2
• 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 2
• 101150033973 Trpc7 gene Proteins 0.000 description 2
• 101150016206 Trpv1 gene Proteins 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 208000005298 acute pain Diseases 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
• RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 2
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 238000006193 diazotization reaction Methods 0.000 description 2
• VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 102000052408 human TRPA1 Human genes 0.000 description 2
• PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• JEHCHYAKAXDFKV-UHFFFAOYSA-J lead tetraacetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000002981 neuropathic effect Effects 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 238000007248 oxidative elimination reaction Methods 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000001301 oxygen Chemical group 0.000 description 2
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Chemical group 0.000 description 2
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000001953 sensory effect Effects 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
• 125000001174 sulfone group Chemical group 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 208000037816 tissue injury Diseases 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
• NRESDXFFSNBDGP-UHFFFAOYSA-N (4-bromophenyl)hydrazine Chemical compound NNC1=CC=C(Br)C=C1 NRESDXFFSNBDGP-UHFFFAOYSA-N 0.000 description 1
• JVJFIQYAHPMBBX-FNORWQNLSA-N (E)-4-hydroxynon-2-enal Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical class N1N=NC(=C1)* 0.000 description 1
• VVSASNKOFCZVES-UHFFFAOYSA-N 1,3-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound CN1C(=O)CC(=O)N(C)C1=O VVSASNKOFCZVES-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• 125000006083 1-bromoethyl group Chemical group 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
• IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
• ZJMRLQDWCQGAGL-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)-n-[4-[2-fluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC=CC(C(F)(F)F)=C1F ZJMRLQDWCQGAGL-UHFFFAOYSA-N 0.000 description 1
• UKQWNCVACIBMIA-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)-n-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC=CC(C(F)(F)F)=C1 UKQWNCVACIBMIA-UHFFFAOYSA-N 0.000 description 1
• WMIAZCXMKZFMFT-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)-n-[4-[3-fluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC=C(C(F)(F)F)C(F)=C1 WMIAZCXMKZFMFT-UHFFFAOYSA-N 0.000 description 1
• AZFDRDILHVHWLJ-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=NSC(CC(O)=O)=C21 AZFDRDILHVHWLJ-UHFFFAOYSA-N 0.000 description 1
• YUKQOUBWKKZSEI-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-(4-ethylphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(CC)=CC=C1C1=CSC(NC(=O)CC=2C=3C(=O)N(C)C(=O)N(C)C=3SN=2)=N1 YUKQOUBWKKZSEI-UHFFFAOYSA-N 0.000 description 1
• LJVBOYNVRPSCQX-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-[2-fluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=CC(C(F)(F)F)=C1F LJVBOYNVRPSCQX-UHFFFAOYSA-N 0.000 description 1
• KGZSYEIVIHQFAV-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(C(F)(F)F)C=C1F KGZSYEIVIHQFAV-UHFFFAOYSA-N 0.000 description 1
• KXWUDADKOUJBPH-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-[2-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC(C(F)(F)F)=CC=C1F KXWUDADKOUJBPH-UHFFFAOYSA-N 0.000 description 1
• BNLZZNSAVFDWBX-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=CC(C(F)(F)F)=C1 BNLZZNSAVFDWBX-UHFFFAOYSA-N 0.000 description 1
• NNSLKBVDAAEDLW-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-[3-fluoro-4-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(OC(F)(F)F)C(F)=C1 NNSLKBVDAAEDLW-UHFFFAOYSA-N 0.000 description 1
• JEPYVPCCTJDATH-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-[3-fluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(C(F)(F)F)C(F)=C1 JEPYVPCCTJDATH-UHFFFAOYSA-N 0.000 description 1
• ODCGQSLLUGLMSU-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC(F)=CC(C(F)(F)F)=C1 ODCGQSLLUGLMSU-UHFFFAOYSA-N 0.000 description 1
• ZDXUTBQSHIJZIT-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-[4-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(OC(F)(F)F)C=C1 ZDXUTBQSHIJZIT-UHFFFAOYSA-N 0.000 description 1
• OBMMAOIHXZHHJE-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)-n-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(C(F)(F)F)=C1 OBMMAOIHXZHHJE-UHFFFAOYSA-N 0.000 description 1
• CCPAKDWOPFVAFO-UHFFFAOYSA-N 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1C(CC(O)=O)=NS2 CCPAKDWOPFVAFO-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
• 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
• 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
• 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
• BJVNRSWYDYTBTC-UHFFFAOYSA-N 3-methylsulfanyl-1,2-thiazole Chemical compound CSC=1C=CSN=1 BJVNRSWYDYTBTC-UHFFFAOYSA-N 0.000 description 1
• XYLSGDNNXDLNED-UHFFFAOYSA-N 4-(2,4-dichloro-5-fluorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC(Cl)=C(F)C=2)Cl)=C1 XYLSGDNNXDLNED-UHFFFAOYSA-N 0.000 description 1
• HKUPOLYVZQLXKP-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC(F)=CC=2)F)=C1 HKUPOLYVZQLXKP-UHFFFAOYSA-N 0.000 description 1
• NDCSJUJQMRFHEX-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(F)C(F)=CC=2)=C1 NDCSJUJQMRFHEX-UHFFFAOYSA-N 0.000 description 1
• IHSQQPRXSGPBTF-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(Cl)C=C(Cl)C=2)=C1 IHSQQPRXSGPBTF-UHFFFAOYSA-N 0.000 description 1
• ZBRNKOLWXWMLTA-UHFFFAOYSA-N 4-(4-bromophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC(Br)=CC=2)=C1 ZBRNKOLWXWMLTA-UHFFFAOYSA-N 0.000 description 1
• MWEXZTFCZYULFR-UHFFFAOYSA-N 4-(4-cyclohexylphenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC(=CC=2)C2CCCCC2)=C1 MWEXZTFCZYULFR-UHFFFAOYSA-N 0.000 description 1
• YDFOGNLELPWXHU-UHFFFAOYSA-N 4-(4-ethylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(CC)=CC=C1C1=CSC(N)=N1 YDFOGNLELPWXHU-UHFFFAOYSA-N 0.000 description 1
• ABCNUVGFUGMTOA-UHFFFAOYSA-N 4-(4-tert-butylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CSC(N)=N1 ABCNUVGFUGMTOA-UHFFFAOYSA-N 0.000 description 1
• QFMNMDDKDKCKKW-UHFFFAOYSA-N 4-[2,3-difluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=C(F)C(=CC=2)C(F)(F)F)F)=C1 QFMNMDDKDKCKKW-UHFFFAOYSA-N 0.000 description 1
• WTMCMRXAHVSYMO-UHFFFAOYSA-N 4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC(=CC=2)C(F)(F)F)F)=C1 WTMCMRXAHVSYMO-UHFFFAOYSA-N 0.000 description 1
• FPIUGVQEXYOXEA-UHFFFAOYSA-N 4-[2-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C=2)C(F)(F)F)F)=C1 FPIUGVQEXYOXEA-UHFFFAOYSA-N 0.000 description 1
• MJWHFCUYRHHBNV-UHFFFAOYSA-N 4-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(Cl)C(OC(F)(F)F)=CC=2)=C1 MJWHFCUYRHHBNV-UHFFFAOYSA-N 0.000 description 1
• MXCYRRLXHVJVHV-UHFFFAOYSA-N 4-[3-chloro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(Cl)C(=CC=2)C(F)(F)F)=C1 MXCYRRLXHVJVHV-UHFFFAOYSA-N 0.000 description 1
• LZKRCDRXVVTLQL-UHFFFAOYSA-N 4-[3-chloro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(C=C(Cl)C=2)C(F)(F)F)=C1 LZKRCDRXVVTLQL-UHFFFAOYSA-N 0.000 description 1
• UKJQCMKGJGFQFQ-UHFFFAOYSA-N 4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(C=C(F)C=2)C(F)(F)F)=C1 UKJQCMKGJGFQFQ-UHFFFAOYSA-N 0.000 description 1
• SDIUFDASQXZLBJ-UHFFFAOYSA-N 4-[4-(difluoromethoxy)-3,5-difluorophenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(F)C(OC(F)F)=C(F)C=2)=C1 SDIUFDASQXZLBJ-UHFFFAOYSA-N 0.000 description 1
• XFGFAEIZTOEDAN-UHFFFAOYSA-N 4-[4-(difluoromethoxy)-3-fluorophenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(F)C(OC(F)F)=CC=2)=C1 XFGFAEIZTOEDAN-UHFFFAOYSA-N 0.000 description 1
• PWVLBESTTRJTFT-UHFFFAOYSA-N 4-[4-(trifluoromethoxy)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC(OC(F)(F)F)=CC=2)=C1 PWVLBESTTRJTFT-UHFFFAOYSA-N 0.000 description 1
• LHLONHMYWKYQCQ-UHFFFAOYSA-N 4-[4-chloro-3-(trifluoromethoxy)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(OC(F)(F)F)C(Cl)=CC=2)=C1 LHLONHMYWKYQCQ-UHFFFAOYSA-N 0.000 description 1
• KGPBNLSPHADRDS-UHFFFAOYSA-N 4-[4-fluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=C1 KGPBNLSPHADRDS-UHFFFAOYSA-N 0.000 description 1
• 125000005986 4-piperidonyl group Chemical group 0.000 description 1
• GPJZEFFHXIVLDM-UHFFFAOYSA-N 5,7-dimethyl-3-methylsulfanyl-[1,2]thiazolo[3,4-d]pyrimidine-4,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C(SC)SN=C21 GPJZEFFHXIVLDM-UHFFFAOYSA-N 0.000 description 1
• LCQSRPGLBHQFNF-UHFFFAOYSA-N 5,7-dimethyl-3-methylsulfonyl-[1,2]thiazolo[3,4-d]pyrimidine-4,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=NSC(S(C)(=O)=O)=C21 LCQSRPGLBHQFNF-UHFFFAOYSA-N 0.000 description 1
• QISLSNOTFIIUEE-UHFFFAOYSA-N 5H-1,2-thiazol-2-amine Chemical compound NN1SCC=C1 QISLSNOTFIIUEE-UHFFFAOYSA-N 0.000 description 1
• VFGRNTYELNYSKJ-UHFFFAOYSA-N 6-amino-1,3-dimethylpyrimidine-2,4-dione Chemical compound CN1C(N)=CC(=O)N(C)C1=O VFGRNTYELNYSKJ-UHFFFAOYSA-N 0.000 description 1
• LNDZXOWGUAIUBG-UHFFFAOYSA-N 6-aminouracil Chemical compound NC1=CC(=O)NC(=O)N1 LNDZXOWGUAIUBG-UHFFFAOYSA-N 0.000 description 1
• LKFGZQGHQPAHMU-UHFFFAOYSA-N 6-chloro-2,4-dioxo-1h-pyrimidine-5-carbaldehyde Chemical compound ClC=1NC(=O)NC(=O)C=1C=O LKFGZQGHQPAHMU-UHFFFAOYSA-N 0.000 description 1
• 240000002234 Allium sativum Species 0.000 description 1
• KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
• 101100350964 Arabidopsis thaliana PANS1 gene Proteins 0.000 description 1
• 244000056139 Brassica cretica Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 206010006438 Bronchial irritation Diseases 0.000 description 1
• NQRIJJHHXWLVJA-UHFFFAOYSA-N CC(N)=O.N1=CN=CC2=NS(=O)(=O)C=C21 Chemical class CC(N)=O.N1=CN=CC2=NS(=O)(=O)C=C21 NQRIJJHHXWLVJA-UHFFFAOYSA-N 0.000 description 1
• BPEVBYFGUHGJME-UHFFFAOYSA-N CC(O)=O.c1cnsc1 Chemical compound CC(O)=O.c1cnsc1 BPEVBYFGUHGJME-UHFFFAOYSA-N 0.000 description 1
• 101150076566 CMR1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-BKFZFHPZSA-N Calcium-45 Chemical compound [45Ca] OYPRJOBELJOOCE-BKFZFHPZSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 208000009132 Catalepsy Diseases 0.000 description 1
• QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 101710178035 Chorismate synthase 2 Proteins 0.000 description 1
• 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
• 101710152694 Cysteine synthase 2 Proteins 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
• 206010015946 Eye irritation Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 208000001034 Frostbite Diseases 0.000 description 1
• JVJFIQYAHPMBBX-UHFFFAOYSA-N HNE Natural products CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 1
• IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
• 101000844510 Homo sapiens Transient receptor potential cation channel subfamily M member 1 Proteins 0.000 description 1
• 101000844503 Homo sapiens Transient receptor potential cation channel subfamily M member 3 Proteins 0.000 description 1
• 101000844519 Homo sapiens Transient receptor potential cation channel subfamily M member 6 Proteins 0.000 description 1
• 101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 206010065390 Inflammatory pain Diseases 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 101150091161 MCOLN1 gene Proteins 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 102400001335 Mucolipin Human genes 0.000 description 1
• 101100520164 Mus musculus Pkdrej gene Proteins 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• QMMDEKJKYIZQAQ-UHFFFAOYSA-N N-([1,2]thiazolo[4,3-d]pyrimidin-3-yl)acetamide Chemical class C1=NC=NC2=C(NC(=O)C)SN=C21 QMMDEKJKYIZQAQ-UHFFFAOYSA-N 0.000 description 1
• 238000007126 N-alkylation reaction Methods 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 101100426589 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) trp-3 gene Proteins 0.000 description 1
• 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
• 238000006645 Posner synthesis reaction Methods 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
• 101100426590 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trp2 gene Proteins 0.000 description 1
• 101100100680 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trp4 gene Proteins 0.000 description 1
• 206010040880 Skin irritation Diseases 0.000 description 1
• 239000004133 Sodium thiosulphate Substances 0.000 description 1
• 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 229940123524 TRPA1 antagonist Drugs 0.000 description 1
• 102000003629 TRPC3 Human genes 0.000 description 1
• 102000003622 TRPC4 Human genes 0.000 description 1
• 102000003621 TRPC5 Human genes 0.000 description 1
• 101150042815 TRPC5 gene Proteins 0.000 description 1
• 102000003617 TRPM1 Human genes 0.000 description 1
• 102000003609 TRPM5 Human genes 0.000 description 1
• 101150059135 TRPM5 gene Proteins 0.000 description 1
• 102000003608 TRPM6 Human genes 0.000 description 1
• 101150045183 TRPM7 gene Proteins 0.000 description 1
• 108091008849 TRPN Proteins 0.000 description 1
• 108010004408 TRPP Cation Channels Proteins 0.000 description 1
• 102100031229 Transient receptor potential cation channel subfamily M member 3 Human genes 0.000 description 1
• 102100031228 Transient receptor potential cation channel subfamily M member 4 Human genes 0.000 description 1
• 102100031232 Transient receptor potential cation channel subfamily M member 7 Human genes 0.000 description 1
• 101710123694 Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 101150037542 Trpc3 gene Proteins 0.000 description 1
• 101150099990 Trpc4 gene Proteins 0.000 description 1
• 101150111943 Trpm4 gene Proteins 0.000 description 1
• 206010047853 Waxy flexibility Diseases 0.000 description 1
• 108010084455 Zeocin Proteins 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 150000003869 acetamides Chemical class 0.000 description 1
• CKNLRWFQBHFLMK-UHFFFAOYSA-N acetic acid;[1,2]thiazolo[3,4-d]pyrimidine 2,2-dioxide Chemical compound CC(O)=O.C1=NC=NC2=NS(=O)(=O)C=C21 CKNLRWFQBHFLMK-UHFFFAOYSA-N 0.000 description 1
• HVVBSKNEHPANPR-UHFFFAOYSA-N acetic acid;[1,2]thiazolo[5,4-d]pyrimidine 1,1-dioxide Chemical compound CC(O)=O.N1=CN=C2S(=O)(=O)N=CC2=C1 HVVBSKNEHPANPR-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 150000001336 alkenes Chemical group 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 229950003476 aminothiazole Drugs 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 239000000058 anti acne agent Substances 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000002682 anti-psoriatic effect Effects 0.000 description 1
• 230000001153 anti-wrinkle effect Effects 0.000 description 1
• 229940124340 antiacne agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000002282 antimigraine agent Substances 0.000 description 1
• 229940125684 antimigraine agent Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000011260 aqueous acid Substances 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 125000002785 azepinyl group Chemical group 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 125000005872 benzooxazolyl group Chemical group 0.000 description 1
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 206010007776 catatonia Diseases 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 235000017803 cinnamon Nutrition 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000258 cyclohexylethoxy group Chemical group [H]C([H])(O*)C([H])([H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 229940009976 deoxycholate Drugs 0.000 description 1
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
• OQPSYEXPZHEKDZ-UHFFFAOYSA-N diethyl 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)propanedioate Chemical compound CN1C(=O)N(C)C(=O)C2=C(C(C(=O)OCC)C(=O)OCC)SN=C21 OQPSYEXPZHEKDZ-UHFFFAOYSA-N 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 125000005879 dioxolanyl group Chemical group 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000012039 electrophile Substances 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• IEMGWBMVQLVHEY-UHFFFAOYSA-N ethyl 2-(3-amino-6,7-dihydro-5h-cyclopenta[b]pyridin-7-yl)acetate Chemical compound NC1=CN=C2C(CC(=O)OCC)CCC2=C1 IEMGWBMVQLVHEY-UHFFFAOYSA-N 0.000 description 1
• DLFDWUHQMMYCQT-UHFFFAOYSA-N ethyl 2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetate Chemical compound CN1C(=O)N(C)C(=O)C2=C(CC(=O)OCC)SN=C21 DLFDWUHQMMYCQT-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 231100000013 eye irritation Toxicity 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 235000004611 garlic Nutrition 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 239000003966 growth inhibitor Substances 0.000 description 1
• 230000003779 hair growth Effects 0.000 description 1
• 230000026030 halogenation Effects 0.000 description 1
• 238000005658 halogenation reaction Methods 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 239000002085 irritant Substances 0.000 description 1
• 231100000021 irritant Toxicity 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 150000003854 isothiazoles Chemical class 0.000 description 1
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 239000003410 keratolytic agent Substances 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000003859 lipid peroxidation Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000011344 liquid material Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• MZESBCNFBNEKDE-UHFFFAOYSA-N methyl 4-amino-1,3-dimethyl-2,6-dioxopyrimidine-5-carbodithioate Chemical compound CSC(=S)C1=C(N)N(C)C(=O)N(C)C1=O MZESBCNFBNEKDE-UHFFFAOYSA-N 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
• ADEAXEQTXHDIHA-UHFFFAOYSA-N n-(2-chlorophenyl)-1,3-thiazol-2-amine Chemical compound ClC1=CC=CC=C1NC1=NC=CS1 ADEAXEQTXHDIHA-UHFFFAOYSA-N 0.000 description 1
• FHXWGIBLDBVWKR-UHFFFAOYSA-N n-[3-(4-chlorophenyl)-1,2-oxazol-5-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(ON=1)=CC=1C1=CC=C(Cl)C=C1 FHXWGIBLDBVWKR-UHFFFAOYSA-N 0.000 description 1
• YFDODXYISNKXKN-UHFFFAOYSA-N n-[4-(2,4-dichloro-5-fluorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC(F)=C(Cl)C=C1Cl YFDODXYISNKXKN-UHFFFAOYSA-N 0.000 description 1
• HQTJKBGYEDGTEB-UHFFFAOYSA-N n-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C=C1F HQTJKBGYEDGTEB-UHFFFAOYSA-N 0.000 description 1
• XRZOMCQELMQCEZ-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(F)=C1 XRZOMCQELMQCEZ-UHFFFAOYSA-N 0.000 description 1
• KCZKVXKHCJRGLN-UHFFFAOYSA-N n-[4-(3,5-dichlorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC(Cl)=CC(Cl)=C1 KCZKVXKHCJRGLN-UHFFFAOYSA-N 0.000 description 1
• FAEOCLUITYXFBQ-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 FAEOCLUITYXFBQ-UHFFFAOYSA-N 0.000 description 1
• LRBGOATYMAGCLX-UHFFFAOYSA-N n-[4-(4-cyclohexylphenyl)-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C(C=C1)=CC=C1C1CCCCC1 LRBGOATYMAGCLX-UHFFFAOYSA-N 0.000 description 1
• PYQZVIOQEOMABN-UHFFFAOYSA-N n-[4-[2,3-difluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(C(F)(F)F)C(F)=C1F PYQZVIOQEOMABN-UHFFFAOYSA-N 0.000 description 1
• XCZDOORZBGHHNA-UHFFFAOYSA-N n-[4-[2,4-difluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(F)C(C(F)(F)F)=C1F XCZDOORZBGHHNA-UHFFFAOYSA-N 0.000 description 1
• JANOXSQMKWQIPA-UHFFFAOYSA-N n-[4-[3,5-difluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC(F)=C(C(F)(F)F)C(F)=C1 JANOXSQMKWQIPA-UHFFFAOYSA-N 0.000 description 1
• YAVNENHABAPTST-UHFFFAOYSA-N n-[4-[3,5-difluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC(F)=C(C(F)(F)F)C(F)=C1 YAVNENHABAPTST-UHFFFAOYSA-N 0.000 description 1
• HGJRJRKZFZNQMJ-UHFFFAOYSA-N n-[4-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(OC(F)(F)F)C(Cl)=C1 HGJRJRKZFZNQMJ-UHFFFAOYSA-N 0.000 description 1
• SVWZINJLIOWROA-UHFFFAOYSA-N n-[4-[3-chloro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(C(F)(F)F)C(Cl)=C1 SVWZINJLIOWROA-UHFFFAOYSA-N 0.000 description 1
• VGIRVLGDGSLELS-UHFFFAOYSA-N n-[4-[3-chloro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC(Cl)=CC(C(F)(F)F)=C1 VGIRVLGDGSLELS-UHFFFAOYSA-N 0.000 description 1
• HZSPFWHTBFVEQD-UHFFFAOYSA-N n-[4-[4-(difluoromethoxy)-3,5-difluorophenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[3,4-d]pyrimidin-3-yl)acetamide Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NSC=1CC(=O)NC(SC=1)=NC=1C1=CC(F)=C(OC(F)F)C(F)=C1 HZSPFWHTBFVEQD-UHFFFAOYSA-N 0.000 description 1
• WVLJFLWKLNBOLE-UHFFFAOYSA-N n-[4-[4-(difluoromethoxy)-3-fluorophenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(OC(F)F)C(F)=C1 WVLJFLWKLNBOLE-UHFFFAOYSA-N 0.000 description 1
• VLNXSLIHRXJUAD-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C(OC(F)(F)F)=C1 VLNXSLIHRXJUAD-UHFFFAOYSA-N 0.000 description 1
• CDMIAQZGBMCOOU-UHFFFAOYSA-N n-[5-(4-chlorophenyl)-1h-pyrazol-3-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(NN=1)=CC=1C1=CC=C(Cl)C=C1 CDMIAQZGBMCOOU-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 230000003040 nociceptive effect Effects 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
• 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000005968 oxazolinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 230000008058 pain sensation Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• 150000004031 phenylhydrazines Chemical class 0.000 description 1
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• QGLVEAGMVUQOJP-UHFFFAOYSA-N prop-2-enylboronic acid Chemical compound OB(O)CC=C QGLVEAGMVUQOJP-UHFFFAOYSA-N 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
• BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000000611 regression analysis Methods 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 239000012056 semi-solid material Substances 0.000 description 1
• 210000001044 sensory neuron Anatomy 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 230000036556 skin irritation Effects 0.000 description 1
• 231100000475 skin irritation Toxicity 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000012265 solid product Substances 0.000 description 1
• 230000003238 somatosensory effect Effects 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000001117 sulphuric acid Substances 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
• 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000002769 thiazolinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 108010072897 transcription factor Brn-2 Proteins 0.000 description 1
• 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 1
• 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 101150079396 trpC2 gene Proteins 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1